Treatments using transgenic goat produced antithrombin III

• US 7,019,193 B2
• Filed: 07/02/2002
• Issued: 03/28/2006
• Est. Priority Date: 02/21/1995
• Status: Expired due to Fees

• Current Assignee: rEVO Biologics, Inc. (Agence des Participations de l’Etat)
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: Cole, Edward S., Meade, Harry M., Ditullio, Paul
• Primary Examiner(s): Crouch, Deborah
• Application Number:
  US10/188,658
• Publication Number:
  US 20030096974A1
• Time in Patent Office: 1,365 Days
• Field of Search: 530/393, 800/7, 800 14- 18, 514/12
• US Class Current: 800/7
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07K 14/8128 Antithrombin III
• CPC Class Codes: Y10S 530/832 Milk; colostrum

Abstract

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Claims

1. A method of treating a subject having an ATIII deficiency or inflammation, comprising:

administering to the subject goat mammary gland produced antithrombin III having a monosaccharide composition which comprises a higher level of mannose than plasma derived antithrombin III, wherein thrombin is inhibited.

2. The method of claim 1, wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises fucose.

3. The method of claim 1, wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises GalNAc.

4. The method of claim 1, wherein the mammary gland produced antithrombin III is produced in the mammary glands of a transgenic goat.

5. The method of claim 1, wherein the ATIII deficiency is hereditary ATIII deficiency.

6. The method of claim 1, wherein the ATIII deficiency is acquired ATIII deficiency.

7. A method of treating inflammation in a subject, comprising:

administering to the subject a Moat mammary gland produced antithrombin III having a monosaccharide composition which comprises a higher level of mannose than plasma derived antithrombin III, wherein thrombin is inhibited.

8. The method of claim 7, wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises fucose.

9. The method of claim 7, wherein the mammary gland produced antithrombin III further has a monosaccharide composition which comprises GaINAc.

10. The method of claim 7, wherein the mammary gland produced antithrombin III is produced in the mammary glands of a transgenic goat.